Abstract

    Open Access Commentary Article ID: OJPG-9-113

    A sirtuin 6 activator in the pipeline: New perspectives in depressive disorder treatment

    Ana Carolina de Oliveira Pereira, Gabriel Almeida Mendonça da Silva, José C. Barros and Raoni Schroeder Borges Gonçalves*

    Major Depressive Disorder (MDD) is among the most prevalent mental illnesses worldwide. Its symptoms include persistent feelings of sadness, loss of interest in previously enjoyed activities, and a lack of motivation for daily tasks. While FDA-approved medications are available, they often come with side effects, especially those targeting monoamine neurotransmitters like SSRIs and SNRIs. Thus, there is a need for innovative medications with different mechanisms of action. Sp-624, a derivative of griseofulvin, is currently undergoing clinical trials for MDD treatment. It acts as a sirtuin 6 (SIRT6) activator, offering a novel approach to treating this disorder. This article discusses the biochemical aspects related to the mechanism of action of sp-624, provides a brief overview of related patents, and highlights ongoing clinical trials involving this substance. 

    Keywords:

    Published on: Apr 30, 2024 Pages: 1-4

    Full Text PDF Full Text HTML DOI: 10.17352/ojpg.000013
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

    Indexing/Archiving

    Pinterest on OJPG